Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study

Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study

Abstract Introduction Plasma circulating tumor DNA (ctDNA) is an ideal approach to detecting the epidermal growth factor receptor (EGFR) T790M mutation, which is a major mechanism of resistance to first-generation EGFR-tyrosine kinase inhibitor (TKI) therapy. The present study aimed to explore the a...

Full description

Bibliographic Details
Main Authors: Shirong Zhang, Lucheng Zhu, Bing Xia, Enguo Chen, Qiong Zhao, Xiaochen Zhang, Xueqin Chen, Xufeng Chen, Shenglin Ma
Format: Article
Language:English
Published: Wiley 2018-05-01
Series:Cancer Communications
Subjects:
Non-small cell lung cancer
Epidermal growth factor receptor
T790M
ctDNA
Failure sites
Online Access:http://link.springer.com/article/10.1186/s40880-018-0303-2

Internet

http://link.springer.com/article/10.1186/s40880-018-0303-2

Similar Items